Priyanka Grover
Stock Analyst at J.P. Morgan
(0.13)
# 4,802
Out of 5,152 analysts
40
Total ratings
19.4%
Success rate
-25.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Priyanka Grover
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BBOT BridgeBio Oncology Therapeutics | Maintained: Buy | $17 | $1.98 | +758.59% | 5 | Nov 18, 2026 | |
| NUVB Nuvation Bio | Maintained: Buy | n/a | $3.84 | - | 4 | Nov 17, 2026 | |
| NGNE Neurogene | Maintained: Buy | $63 | $23.30 | +170.39% | 3 | Nov 17, 2026 | |
| KURA Kura Oncology | Maintained: Buy | $30 → $32 | $7.09 | +351.34% | 4 | Nov 17, 2026 | |
| RXRX Recursion Pharmaceuticals | Rated: Buy | $7 | $2.91 | +140.96% | 4 | Nov 16, 2026 | |
| RCUS Arcus Biosciences | Rated: Buy | $41 → $40 | $16.86 | +137.25% | 2 | Nov 9, 2026 | |
| RYTM Rhythm Pharmaceuticals | Reiterated: Buy | $145 → $142 | $107.48 | +32.12% | 5 | Nov 6, 2026 | |
| ELVN Enliven Therapeutics | Initiated Coverage: Buy | $75 | $47.62 | +57.50% | 1 | Oct 1, 2026 | |
| MREO Mereo BioPharma Group | Reiterated: Sell | n/a | $0.305 | - | 9 | Sep 15, 2026 | |
| RLAY Relay Therapeutics | Reiterated: Buy | $31 | $17.27 | +79.50% | 3 | Aug 14, 2026 |
BridgeBio Oncology Therapeutics
Nov 18, 2026
Maintained: Buy
Price Target: $17
Current: $1.98
Upside: +758.59%
Nuvation Bio
Nov 17, 2026
Maintained: Buy
Price Target: n/a
Current: $3.84
Upside: -
Neurogene
Nov 17, 2026
Maintained: Buy
Price Target: $63
Current: $23.30
Upside: +170.39%
Kura Oncology
Nov 17, 2026
Maintained: Buy
Price Target: $30 → $32
Current: $7.09
Upside: +351.34%
Recursion Pharmaceuticals
Nov 16, 2026
Rated: Buy
Price Target: $7
Current: $2.91
Upside: +140.96%
Arcus Biosciences
Nov 9, 2026
Rated: Buy
Price Target: $41 → $40
Current: $16.86
Upside: +137.25%
Rhythm Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $145 → $142
Current: $107.48
Upside: +32.12%
Enliven Therapeutics
Oct 1, 2026
Initiated Coverage: Buy
Price Target: $75
Current: $47.62
Upside: +57.50%
Mereo BioPharma Group
Sep 15, 2026
Reiterated: Sell
Price Target: n/a
Current: $0.305
Upside: -
Relay Therapeutics
Aug 14, 2026
Reiterated: Buy
Price Target: $31
Current: $17.27
Upside: +79.50%